222978-01-0

Basic information

• Product Name: (4-BROMO-3-FLUOROPHENYL)METHANOL
• Synonyms: (4-BROMO-3-FLUOROPHENYL)METHANOL;4-Bromo-3-fluorobenzenemethanol;BenzeneMethanol, 4-broMo-3-fluoro-
• CAS NO: 222978-01-0
• Molecular Formula: C₇H₆BrFO
• Molecular Weight: 205.02
• Mol File: 222978-01-0.mol

Chemical Properties

• Melting Point: 44.0 to 48.0 °C
• Boiling Point: 260℃
• Flash Point: 111℃
• Appearance: /
• Density: 1.658
• Vapor Pressure: 0.00645mmHg at 25°C
• Refractive Index: 1.566
• Storage Temp.: Sealed in dry,Room Temperature
• Solubility: soluble in Methanol
• PKA: 13.70±0.10(Predicted)
• CAS DataBase Reference: (4-BROMO-3-FLUOROPHENYL)METHANOL(CAS DataBase Reference)
• NIST Chemistry Reference: (4-BROMO-3-FLUOROPHENYL)METHANOL(222978-01-0)
• EPA Substance Registry System: (4-BROMO-3-FLUOROPHENYL)METHANOL(222978-01-0)

Safety Data

• Hazardous Substances Data: 222978-01-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(4-Bromo-3-fluorophenyl)methanol is used as a versatile building block for the synthesis of biologically active molecules, including pharmaceuticals. Its unique structure allows for the creation of diverse compounds with potential therapeutic effects.
Used in Agrochemical Industry:
In the agrochemical industry, (4-Bromo-3-fluorophenyl)methanol is utilized as a building block for the development of new agrochemicals, such as pesticides and herbicides, due to its potential to form biologically active molecules.
Used in Antimicrobial Applications:
(4-Bromo-3-fluorophenyl)methanol is studied for its antimicrobial properties, making it a potential candidate for use in applications requiring the inhibition of microbial growth, such as in medical or industrial settings.
Used in Antifungal Applications:
Similarly, its antifungal properties position (4-Bromo-3-fluorophenyl)methanol as a potential agent in combating fungal infections or controlling fungal growth in various industries, including agriculture and healthcare.
Overall, the compound's unique structure and chemical properties contribute to its wide range of potential applications across different industries, highlighting its versatility and value in organic synthesis and beyond.

InChI:InChI=1/C7H6BrFO/c8-6-2-1-5(4-10)3-7(6)9/h1-3,10H,4H2

Upstream product

• 153556-42-4 4-bromo-3-fluorobenzoic acid 
• 452-74-4 4-bromo-3-fluorotoluene 
• 133059-43-5 4-bromo-3-fluorobenzaldehyde 
• 849758-12-9 methyl 4-bromo-3-fluorobenzoate 
• 127425-73-4 1-bromo-4-(bromomethyl)-2-fluorobenzene 

Downstream Products

• 222978-02-1 2-fluoro-4-(hydroxymethyl)benzonitrile 
• 1009334-17-1 (4-bromo-3-fluoro-benzyloxy)-triisopropyl-silane 
• 133059-43-5 4-bromo-3-fluorobenzaldehyde 
• 127425-73-4 1-bromo-4-(bromomethyl)-2-fluorobenzene 
• 1240286-88-7 4-Bromo-3-fluorobenzyl methanesulfonate 
• 1155264-47-3 C₇H₅BrF₂ 
• 499983-13-0 2-( 4-bromo-3-fluorophenyl)acetonitrile 
• 57848-46-1 4-bromo-2-fluorobenzaldehyde 
• 1267502-65-7 (4-ethynyl-2-fluoro-phenyl)-methanol 
• 1267502-66-8 methanesulfonic acid 4-ethynyl-2-fluoro-benzyl ester 
• 1267502-67-9 diethyl-(4-ethynyl-2-fluoro-benzyl)-amine 
• 1331945-14-2 (2-fluoro-4-(hydroxymethyl)phenyl)boronic acid 
• 1314141-37-1 2-(4-(bromomethyl)-2-fluorophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane 

Relevant articles and documents

METHODS OF TREATING HEMATOLOGICAL MALIGNANCIES USING 2-(2,6-DIOXOPIPERIDIN-3-YL)-4-((2-FLUORO-4-((3-MORPHOLINOAZETIDIN-1-YL)METHYL)BENZYL)AMINO)ISOINDOLINE-1,3-DIONE

Provided herein are methods of using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione, or an enantiomer, a mixture of enantiomers, a tautomer, an isotopolog, or a pharmaceutically acceptable salt thereof, for treating, preventing or managing hematological malignancies.

METHODS OF TREATING CHRONIC LYMPHOCYTIC LEUKEMIA USING 2-(2,6-DIOXOPIPERIDIN-3-YL)-4-((2-FLUORO-4-((3-MORPHOLINOAZETIDIN-1-YL)METHYL)BENZYL)AMINO)ISOINDOLINE-1,3-DIONE

Provided herein are methods of using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione, or an enantiomer, a mixture of enantiomers, a tautomer, an isotopolog, or a pharmaceutically acceptable salt thereof, alone or in combination with obinutuzumab, for treating, preventing or managing chronic lymphocytic leukemia/small lymphocytic lymphoma.

SELECTIVE FLUORESCENT PROBE FOR ALDEHYDE DEHYDROGENASE

High aldehyde dehydrogenase 1A1 (ALDH1A1) activity has emerged as a reliable marker for the identification of both normal and cancer stem cells. Herein, is presented AlDeSense, a turn-on green fluorescent probe for aldehyde dehydrogenase 1A1 (ALDH1A1) and Ctrl-AlDeSense, a matching non-responsive reagent. AlDeSense exhibits a 20-fold fluorescent enhancement when treated with ALDH1A1. Through the application of surface marker antibody staining, tumorsphere assays, and assessment of tumorigenicity, the disclosed results show that cells exhibiting high AlDeSense signal intensity have properties of cancer stem cells. Herein, is also reported the development of a red congener, red-AlDeSense. Importantly, red-AlDeSense represents one of only a few examples of a turn-on sensor in the red region using the d-PeT quenching mechanism.

METHODS OF TREATING NON-HODGKIN LYMPHOMA USING 2-(2,6-DIOXOPIPERIDIN-3-YL)-4-((2-FLUORO-4-((3-MORPHOLINOAZETIDIN-1-YL)METHYL)BENZYL)AMINO)ISOINDOLINE-1,3-DIONE

Provided herein are methods of using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione, or an enantiomer, a mixture of enantiomers, a tautomer, an isotopolog, or a pharmaceutically acceptable salt thereof, alone or in combination with rituximab, for treating, preventing or managing non-Hodgkin lymphoma.

AROMATIC ACETYLENE OR AROMATIC ETHYLENE COMPOUND, INTERMEDIATE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF

Disclosed are an aromatic acetylene or aromatic ethylene compound, an intermediate, a preparation method, a pharmaceutical composition and a use thereof. The aromatic acetylene or aromatic ethylene compound has a significant inhibitory effect on PD-1 and PD-L1, and can effectively relieve or treat cancers and other related diseases.

SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH

Provided herein are 4-aminoisoindoline-1,3-dione compounds having the following structure: wherein R, Ring A, and n are as defined herein, compositions comprising an effective amount of a 4-aminoisoindoline-1,3-dione compound, and methods for treating or preventing disorders.

Design, synthesis, biological evaluation and in vivo testing of dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors for the treatment of Alzheimer's disease

We have identified chemical probes that act as dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors (>1 log unit difference versus class I HDACs) to decipher the contribution of HDAC isoforms to the positive impact of dua

BENZOTHIOPHENE DERIVATIVE

[Problem to be Solved] It is intended to provide a compound having PDE10A inhibitory activity and having a novel structure, or an isotope thereof or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same as an active ingredient. [Solution] The present invention provides a compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof.

THERAPEUTIC INHIBITORY COMPOUNDS

The invention provides compounds of Formula I and Formula II: A-B-C-D-E-F-G-J (I) C-D-E-F-G-J (II) wherein A, B, C, D, E, F, G, and J have any of the values defined in the specification, and salts thereof. The compounds are useful for inhibiting plasma kallikrein, and for treating a disease or condition in an animal where inhibition of plasma kallikrein is indicated.

ANTIDIABETIC TRICYCLIC COMPOUNDS

Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR 40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds may be useful in the treatment of Type 2 diabetes mellitus and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.